This marks the first approval of a CRISPR-based therapy for human use, underlining CRISPR's potential to enhance human health significantly.
Additionally, there is anticipation for the approval of Vertex and CRISPR Therapeutics' collaboration for a CRISPR-based sickle cell disease treatment, exagamglogene autotemcel (exa-cel), which is expected to be granted in Europe this year. This marks the first approval of a CRISPR-based therapy for human use, underlining CRISPR's potential to enhance human health significantly.